



## Aduro Biotech Announces Upcoming Data Presentations at the 2017 American Association for Cancer Research Annual Meeting

March 6, 2017

BERKELEY, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced data presentations relating to its technology platforms to be given at the [2017 American Association for Cancer Research Annual Meeting](#) taking place in Washington, D.C., April 1 through April 5, 2017.

Abstract 2645: [Development of a first in class APRIL fully blocking antibody BION-1301 for the treatment of multiple myeloma](#)

Date/Time: Monday, April 3, 1:00 p.m. to 5:00 p.m. ET  
Location: Convention Center, Halls A-C  
Poster section 26; Board number 4

Abstract 2993: [STING signaling in breast tumor microenvironment modulates immune checkpoint blockade efficacy in the neu-N mouse model of breast cancer](#)

Date/Time: Monday, April 3, 3:05 p.m. to 3:20 p.m. ET  
Location: Room 152, Level 1, Washington Convention Center  
Session: Innate Immune Mechanisms in Cancer Treatment - Oral Presentation

### **Late-Breaking Research:** **Immunology**

Abstract LB-198: [Combination of PEGylated recombinant hyaluronidase PH20 \(PEGPH20\) with live-attenuated, double-deleted \(L ADD\) Listeria enhances tumor infiltrating CD8+ T cell response and antitumor efficacy in mice](#)

Date/Time: Tuesday, April 4, 8:00 a.m. to 12:00 p.m. ET  
Location: Convention Center, Halls A-C  
Poster section 35; Board number 21

### **About Aduro**

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of *Listeria* that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient's tumor. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro's B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit [www.aduro.com](http://www.aduro.com).

### *Cautionary Note on Forward-Looking Statements*

*This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, our technology platforms, plans, and the potential for eventual regulatory approval of our product candidates. In some cases, you can identify these statements by forward-looking words such as "may," "will," "continue," "anticipate," "intend," "could," "project," "seek," "expect" or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in*

*greater detail under the heading "Risk Factors" contained in our annual report on Form 10-K for the year ended December 31, 2016, which is on file with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.*

Contact:

Sylvia Wheeler  
SVP, Corporate Affairs  
510 809 9264

Media Contact:

Susan Lehner  
510 809 2137  
[press@aduro.com](mailto:press@aduro.com)



Aduro Biotech, Inc.